Literature DB >> 11000611

Molecular prognostic markers in pancreatic cancer.

D Coppola1.   

Abstract

BACKGROUND: Pancreatic cancer is one of the most aggressive human tumors and is virtually incurable. Its incidence in the United States has tripled in the past 50 years. The tumor is a frequent cause of cancer death in both men and women. The current treatment options are inadequate and probably reflect the fact that the etiologic factors and the pathogenesis of pancreatic cancer are unknown.
METHODS: The author reviewed recent studies describing some of the molecular alterations that may play a role in pancreatic carcinogenesis.
RESULTS: Most pancreatic tumors arise in the ductal epithelium. Cytogenetic abnormalities and alterations in proliferation, oncogenes and tumor suppressor genes, cell receptors, and growth factors are described.
CONCLUSIONS: Preliminary studies have implicated, among others, the insulin-like growth factor-1 receptor, Src, and Stat3 proteins in human pancreatic carcinogenesis. These molecules may represent important predictors of tumor behavior and targets of novel therapeutic modalities in human pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000611     DOI: 10.1177/107327480000700504

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  25 in total

1.  New tumor-associated antigen SC6 in pancreatic cancer.

Authors:  Min-Pei Liu; Xiao-Zhong Guo; Jian-Hua Xu; Di Wang; Hong-Yu Li; Zhong-Min Cui; Jia-Jun Zhao; Li-Nan Ren
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

2.  p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.

Authors:  Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

3.  Mechanism for Src activation by the CCK2 receptor: Patho-physiological functions of this receptor in pancreas.

Authors:  Audrey Ferrand; Sebastien Vatinel; Aline Kowalski-Chauvel; Claudine Bertrand; Chantal Escrieut; Daniel Fourmy; Marlene Dufresne; Catherine Seva
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

4.  Identification and characterization of endonuclein binding proteins: evidence of modulatory effects on signal transduction and chaperone activity.

Authors:  Maja Ludvigsen; Morten Østergaard; Henrik Vorum; Christian Jacobsen; Bent Honoré
Journal:  BMC Biochem       Date:  2009-12-22       Impact factor: 4.059

5.  Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.

Authors:  Jose G Trevino; Justin M Summy; Donald P Lesslie; Nila U Parikh; David S Hong; Francis Y Lee; Nicholas J Donato; James L Abbruzzese; Cheryl H Baker; Gary E Gallick
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

Review 6.  Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.

Authors:  John Araujo; Christopher Logothetis
Journal:  Cancer Treat Rev       Date:  2010-03-11       Impact factor: 12.111

Review 7.  Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved.

Authors:  Markus Stenner; J Peter Klussmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

8.  Overexpression of annexin 1 in pancreatic cancer and its clinical significance.

Authors:  Xiao-Feng Bai; Xiao-Guang Ni; Ping Zhao; Shang-Mei Liu; Hui-Xin Wang; Bing Guo; Lan-Ping Zhou; Fang Liu; Jin-Sheng Zhang; Kun Wang; Yong-Qiang Xie; Yong-Fu Shao; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

9.  Differing Src signaling levels have distinct outcomes in Drosophila.

Authors:  Marcos Vidal; Stephen Warner; Renee Read; Ross L Cagan
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

Review 10.  Targeting angiogenesis in pancreatic cancer: rationale and pitfalls.

Authors:  Chery Whipple; Murray Korc
Journal:  Langenbecks Arch Surg       Date:  2008-01-22       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.